In the article, originally published by Select Science in August 2021 special feature on Cell-based assays (selectscience.net), Tillman explains how he and his Akero teammates have been working with iLite® cell-based assays from Svar Life Science in their pioneering work developing treatments for non-alcoholic steatohepatitis (NASH), a severe form of NAFLD that increases the risk for cardiovascular and liver-related morbidity and mortality.
The iLite cell-based assays have allowed Akero to get crucial insights into the biological activity of the molecule under study – which was not possible using ligand binding assays.
Dr. Tillman especially appreciated the low variability over time and between lots, as well as the speed at which the custom cell lines were developed and produced.
Learn more about this exciting research and find out what challenges there are, and how they can be overcome.
The iLite cell lines are available both as off-the-shelf products for common targets, and as custom-made cell lines to suit a customer's specific need.
All cells are delivered “assay ready”, which means that you can save time and money by not culturing your own cells, as well as ensures excellent reproducibility and performance.
In addition to a luciferase reporter gene, most iLite cell lines contain a secondary reporter gene that can be used for normalizing purposes and for compensating for differences in cell numbers which is a great advantage as you no longer need to count the number of cells in each well.
